Cannabis while breastfeeding

TL;DR

• THC is lipophilic and concentrates in breast milk (up to 8× plasma).
• Bertrand (2018, Pediatrics): detectable up to 6 days after use.
• Infant effects: sedation, motor delay possible (Astley 1990).
• Clear recommendation: do not combine breastfeeding with cannabis.

If you can't fully stop

Pump-and-dump doesn't work for THC — it stores in fat tissue and releases over days.

If use is unavoidable: minimize, use after feeding, maximize the interval.

Talk with a midwife or lactation consultant about alternatives (formula, donor milk).

Pharmacokinetics of cannabinoids in breast milk

Cannabinoids such as THC and CBD possess a pronounced lipophilicity, meaning they preferentially dissolve in fat-rich tissue. Since breast milk has a high fat content to provide optimal nutrition for the infant, these substances cross the blood-milk barrier with great ease. Once in the milk, they bind to the fat globules contained within it, which can lead to a concentration that exceeds the maternal blood plasma level. Due to the slow release from maternal fat stores, the active substances are continuously released into the milk over several days.

The infant's organism is not prepared for these exogenous substances. The enzymatic degradation pathways in the immature liver of the newborn are not yet fully developed, which is why the infant can only metabolise the ingested cannabinoids extremely slowly. This leads to cumulative storage in the child's nervous tissue and brain. Since the child's endocannabinoid system is in a critical phase of development, any external stimulation of this system by maternal THC can severely disrupt natural neural connectivity and receptor formation.

• High lipophilicity facilitates transfer across the biological blood-milk barrier.
• Accumulation in the fatty components of breast milk leads to increased concentration.
• Delayed degradation in the infant due to incompletely developed liver enzymes.
• Potential influence on the infantile endocannabinoid system during brain development.

Swiss guidelines and medical classification

In Switzerland, the legal situation regarding cannabis is clearly defined, but in the medical context of breastfeeding, special precautionary measures apply. Although medical cannabis has been prescribable by doctors without an exceptional permit from the Federal Office of Public Health (BAG) since August 2022, strict clinical reservations exist for breastfeeding mothers. Swiss professional societies for gynaecology and paediatrics emphasise that a prescription during breastfeeding may only be issued after an extremely rigorous risk-benefit assessment, as the safety of the child is the primary concern.

Mothers who have questions about potential exposure or prescribed cannabinoid-containing medications will find structured support in Switzerland. In addition to treating gynaecologists and midwives, the national emergency number for poisoning, Tox Info Suisse (145), offers scientifically sound and free advice in case of uncertainty. Collaboration between cantonal maternity clinics and paediatric departments ensures that affected families receive evidence-based information that is free from moral prejudice and focuses purely on the child's well-being.

• Medical cannabis has been prescribable without a BAG exceptional permit since August 2022, but remains a rare exception during breastfeeding.
• Due to the insufficient data, Swissmedic and the BAG consistently advise against consumption.
• Tox Info Suisse (telephone 145) serves as a competent point of contact in the event of accidental exposure of the infant.
• Interdisciplinary care by Swiss midwives and paediatricians promotes risk minimisation.

Dangers from contamination and synthetic products

An often overlooked risk of consuming non-medical cannabis during breastfeeding is the unclear purity of products on the illegal market. These products can be contaminated with heavy metals, pesticides or moulds, which also pass into breast milk and directly endanger the health of the infant. Particularly worrying is the emergence of synthetic cannabinoids. These artificial substances exhibit unpredictable toxicity and a many times higher binding affinity to receptors, which can lead to severe neurological deficits in the child.

Even over-the-counter CBD products, which are often declared as harmless wellness preparations, are not subject to the strict quality controls of medicinal products. Analyses repeatedly show that such products can contain unexpected amounts of psychoactive THC or solvent residues. Since there is no safe dose of these substances for the infant, Swiss authorities recommend abstaining from any unregulated hemp products throughout the entire breastfeeding period in order to completely rule out any unconscious transmission of harmful substances via breast milk.

• Illegal cannabis products carry the risk of toxic contamination such as pesticides or heavy metals.
• Synthetic cannabinoids possess extremely high potency and pose an acute danger to the child.
• Over-the-counter CBD products often exhibit labeling deficiencies and unwanted THC residues.
• Avoiding unregulated preparations protects the infant from unpredictable chemical exposure.

FAQ